Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 plus pemetrexed versus placebo plus pemetrexed in second-line advanced non-squamous non-small cell lung cancer
2013-004698-29Phase 2Terminated
- Sponsor
- Threshold Pharmaceuticals
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TH-302 + pemetrexed with placebo + pemetrexed (2 arms). Primary endpoint: overall survival. Started Feb 2014; status: terminated.
02
Drugs
evofosfamidepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004698-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004698-29.